オプションチェーンは、UnitedHealth Groupの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、UnitedHealth Groupの市場センチメントを評価します。.

UnitedHealth Group (NYSE:UNH) 株価情報, オプションチェーン

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</h3>
<ul>
<li>On April 21, UnitedHealth reported worse-than-expected first-quarter results and cut its FY25 adjusted EPS guidance below estimates. "UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead, and return to our long-term earnings growth rate target of 13 to 16%," said Andrew Witty, CEO of UnitedHealth. The company's stock fell around 19% over the past month and has a 52-week low of $412.02.</li>
<li>RSI Value: 27.1</li>
<li>UNH Price Action: Shares of UnitedHealth fell 1.3% to close at $418.64 on Friday.</li>
<li>Edge Stock Ratings: 26.37 Momentum score with Value at 69.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/UNH"><img loading="lazy" decoding="async" width="481" height="192" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png" alt="" class="wp-image-890598" style="width:331px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186.png 481w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28070358/image-186-300x120.png 300w" sizes="(max-width: 481px) 100vw, 481px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;&nbsp;</h3>
<ul>
<li>On April 24, Bristol Myers Squibb reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 billion. &#8220;Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline,&#8221; said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. The company's stock fell around 20% over the past month and<a href="https://www.benzinga.com/quote/BMY"> has a 52-week low</a> of $39.35.</li>
<li>RSI Value: 25</li>
<li>BMY Price Action: Shares of Bristol-Myers Squibb dipped 1.6% to close at $47.90 on Friday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">BMY stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="916" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png" alt="" class="wp-image-890615" style="width:544px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071255/image-187-768x710.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<h3 class="wp-block-heading">X4 Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>)</h3>
<ul>
<li>On April 24, X4 Pharmaceuticals company announced a 1-for-30 reverse stock split. The company has a 52-week <a href="https://www.benzinga.com/quote/XFOR">low of $0.17.</a></li>
<li>RSI Value: 14.7</li>
<li>XFOR Price Action: Shares of X4 Pharmaceuticals closed at $5.70 on Friday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428">XFOR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0428"><img loading="lazy" decoding="async" width="876" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png" alt="" class="wp-image-890619" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28071347/image-188-768x737.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/45007044/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

XFOR

Top 3 Health Care Stocks That May Rocket Higher In April

These twelve large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) stock tumbled 14.92% after the company issued FY25 adjusted EPS guidance with its midpoint below estimates. Analysts changed <a href="https://www.benzinga.com//node/45013364" target="_blank" rel="noreferrer noopener">their price forecasts</a>.</li>
<li>Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) shares dipped 12.43% after the company reported worse-than-expected results and lowered its FY25 EPS guidance. Several analysts <a href="https://www.benzinga.com//node/44965915" target="_blank" rel="noreferrer noopener">lowered their price forecasts</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) stock plummeted 11.95% after it reported financial results <a href="https://www.benzinga.com//node/44995337" target="_blank" rel="noreferrer noopener">and missed its EPS estimate</a>.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) shares fell 11.17% last week following the <a href="https://www.benzinga.com//node/44995935" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Watsco, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) shares dipped 9.98% after the company reported first-quarter results and <a href="https://www.benzinga.com//node/44945784" target="_blank" rel="noreferrer noopener">missed its EPS and sales estimates</a>. Analysts <a href="https://www.benzinga.com/quote/wso/analyst-ratings" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>Gold Fields (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares decreased 9.13%, probably because gold prices dropped after President Trump said he had no intention of firing Fed Chair Powell and indicated that the final tariff rate with China would be &#8220;substantially&#8221; lower than the current 145%.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) stock fell 8.59% after the company reported financial results and missed its adjusted <a href="https://www.benzinga.com//node/45003204" target="_blank" rel="noreferrer noopener">EPS and revenue estimates</a>.</li>
<li>AngloGold Ashanti PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AU#NYSE">AU</a>) shares fell 8.44%, probably because gold prices dropped after President Trump said he had no intention of firing Fed Chair Powell and indicated that the final tariff rate with China would be &#8220;substantially&#8221; lower than the current 145%.</li>
<li>Ryan Specialty Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAN#NYSE">RYAN</a>) stock was down 8.17%. The company inked a deal to acquire certain assets of USQRisk <a href="https://www.benzinga.com//node/44910617" target="_blank" rel="noreferrer noopener">Holdings for an undisclosed amount</a>.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) stock fell 7.99% last week after the company reported first-quarter results. Several analysts <a href="https://www.benzinga.com/quote/TYL/analyst-ratings" target="_blank" rel="noreferrer noopener">lowered their price forecasts</a>.</li>
<li>Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) stock declined 7.84% after it reported weaker-than-expected first-quarter sales, and several <a href="https://www.benzinga.com//node/44959233" target="_blank" rel="noreferrer noopener">analysts slashed their price forecast</a>.</li>
<li>UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares decreased 7.81%. The company reported disappointing first-quarter results last week, and <a href="https://www.benzinga.com//node/44913470" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
</ol>
Photo by Ken Wolter via Shutterstock

Earnings

Equities

Large Cap

Movers

ERIE

RYAN

TMUS

UnitedHealth, T-Mobile And Fiserv Are Among Top 12 Large-Cap Losers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 30 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 23% leaning bullish and 50% bearish. Among these notable options, 9 are puts, totaling $647,863, and 21 are calls, amounting to $1,860,411.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $230.0 to $560.0 for UnitedHealth Group over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UnitedHealth Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UnitedHealth Group's substantial trades, within a strike price spectrum from $230.0 to $560.0 over the preceding 30 days.
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745593251_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$39.6</td>
<td>$38.85</td>
<td>$39.6</td>
<td>$450.00</td>
<td>$272.3K</td>
<td>109</td>
<td align="right">71</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$41.7</td>
<td>$41.65</td>
<td>$41.75</td>
<td>$400.00</td>
<td>$234.0K</td>
<td>84</td>
<td align="right">71</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$8.85</td>
<td>$8.6</td>
<td>$8.84</td>
<td>$500.00</td>
<td>$221.2K</td>
<td>2.7K</td>
<td align="right">485</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$10.5</td>
<td>$10.0</td>
<td>$10.35</td>
<td>$425.00</td>
<td>$207.0K</td>
<td>243</td>
<td align="right">668</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$147.55</td>
<td>$142.5</td>
<td>$145.0</td>
<td>$280.00</td>
<td>$145.0K</td>
<td>14</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
Following our analysis of the options activities associated with UnitedHealth Group, we pivot to a closer look at the company's own performance.
<h3>UnitedHealth Group's Current Market Status</h3>
<ul>
<li>With a volume of 2,705,682, the price of UNH is down -2.7% at $412.78. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 81 days.</li>
</ul>
<h3>What The Experts Say On UnitedHealth Group</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $542.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Keybanc continues to hold a Overweight rating for UnitedHealth Group, targeting a price of $575. 
&#x2A; An analyst from Raymond James has revised its rating downward to Strong Buy, adjusting the price target to $540. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for UnitedHealth Group, targeting a price of $513. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on UnitedHealth Group with a target price of $525. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on UnitedHealth Group with a target price of $560. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Check Out What Whales Are Doing With UNH

WIIM

UnitedHealth Group shares are trading lower after Barclays cut its price target on the stock from $560 to $513.

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $560 to $513.

Price Target

Analyst Ratings

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $513

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>UBS raised General Dynamics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) price target from $268 to $279. UBS analyst Gavin Parsons maintained a Neutral rating. General Dynamics shares closed at $265.73 on Wednesday. <a href="https://www.benzinga.com/quote/GD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut the price target for Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) from $160 to $145. Morgan Stanley maintained an Overweight rating. Valero Energy shares closed at $114.50 on Wednesday. <a href="https://www.benzinga.com/quote/VLO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim boosted ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) price target from $716 to $724. Guggenheim analyst John Difucci maintained a Sell rating. ServiceNow shares closed at $812.70 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/NOW/analyst-ratings">view this stock</a>.</li>
<li>Citigroup cut the price target for AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) from $2.8 to $2.3. Citigroup analyst Jason Bazinet maintained a Sell rating. AMC shares closed at $2.71 on Wednesday. <a href="https://www.benzinga.com/quote/AMC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Cantor Fitzgerald cut the price target for Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) from $200 to $170. Cantor Fitzgerald analyst Matthew Prisco maintained a Neutral rating. Texas Instruments shares closed at $152.15 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/TXN/analyst-ratings">view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods cut Trustmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) price target from $45 to $43. Keefe, Bruyette &amp; Woods analyst Catherine Mealor maintained an Outperform rating. Trustmark shares settled at $33.88 on Wednesday. <a href="https://www.benzinga.com/quote/TRMK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan slashed UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) price target from $652 to $525. JP Morgan analyst Lisa Gill maintained an Overweight rating. UnitedHealth shares closed at $427.96 on Wednesday. <a href="https://www.benzinga.com/quote/UNH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>) price target from $260 to $248. Piper Sandler analyst Adam Maeder maintained a Neutral rating. ResMed shares closed at $214.44 on Wednesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank cut the price target for Freshworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) from $19 to $14. Scotiabank analyst Nick Altmann maintained a Sector Perform rating. Freshworks shares settled at $12.78 on Wednesday. <a href="https://www.benzinga.com/quote/FRSH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel slashed Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) price target from $455 to $450. Stifel analyst Stephen Gengaro maintained a Buy rating. Tesla shares closed at $250.74 on Wednesday. <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying TSLA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24132433/image-156-1024x595.png" alt="" class="wp-image-887193" style="width:620px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24132433/image-156-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24132433/image-156-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24132433/image-156-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/24132433/image-156.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a> </li>
</ul>
Photo via Shutterstock

FRSH

TRMK

TSLA

Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday

JP Morgan analyst Lisa Gill maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $652 to $525.

JP Morgan Maintains Overweight on UnitedHealth Group, Lowers Price Target to $525

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/23/final-trades-salesforce-unitedhealth-western-union-and-howmet-aerospace.html">Halftime Report Final Trades</a>,&#8221; Sarat Sethi, managing partner at DCLA, said he loves Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>).
Supporting his view, Guggenheim analyst John Difucci upgraded Salesforce from Sell to Neutral on Monday.
Stephen L. Weiss of Short Hills Capital Partners chose UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), saying the stock has bottomed.
On the earnings front, UnitedHealth reported first-quarter revenue of $109.58 billion on Monday, missing analyst estimates of $ 111.6 billion, according to Benzinga Pro. The company reported first-quarter adjusted earnings of $7.20 per share, missing estimates of $7.29 per share.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management, LLC, said The Western Union Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WU#NYSE">WU</a>) is being overly sold off due to irrational fears.
After the closing bell on Wednesday, Western Union posted first-quarter adjusted earnings of 41 cents per share, in line with market estimates. The company's sales came in at $983.60 million, missing expectations of $994.64 million.
Joseph M. Terranova of Virtus Investment Partners picked Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) as his final trade.
Lending support to his choice, Benchmark analyst Josh Sullivan, on Monday, maintained Howmet Aerospace with a Buy rating and raised the price target from $85 to $135.
Price Action:
<ul>
<li>Salesforce shares jumped 2.9% to close at $250.48 on Wednesday.</li>
<li>UnitedHealth gained 0.2% to close at $427.96 during Wednesday's session.</li>
<li>Western Union shares rose 1.1% to close at $10.11 on Wednesday.</li>
<li>Howmet Aerospace shares climbed 4.3% to settle at $129.70 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/04/44948767/top-2-consumer-stocks-that-may-implode-this-month">Top 2 Consumer Stocks That May Implode This Month</a></li>
</ul>
Photo: Shutterstock

Media

General

UnitedHealth, Salesforce, Howmet Aerospace And A Financial Stock: CNBC's 'Final Trades'

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 19.05%. Currently, UnitedHealth Group has a market capitalization of $389.54 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 15 years ago, it would be worth $1,405.91 today based on a price of $427.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745443826_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 15 Years

RBC Capital analyst Ben Hendrix maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $655 to $525.

RBC Capital Maintains Outperform on UnitedHealth Group, Lowers Price Target to $525

CNBC Halftime Report Final Trades: Salesforce, UnitedHealth Group, The Western Union, Howmet Aerospace

Elevance Health Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) on Tuesday reported first-quarter 2025 revenues of $48.77 billion, up 15% year-over-year, higher than the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $46.29 billion</a>.&nbsp;
The increase was driven by higher premium yields in the Health Benefits segment, acquisitions completed in the past year, Medicare Advantage and Individual ACA membership growth, and CarelonRx product revenue, partially offset by membership <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44917011/elevance-health-reports-first-quarter-2025-results" rel="noreferrer noopener">attrition in Medicaid business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44675802/health-insurers-surge-after-medicare-agency-increases-payment-rates" rel="noreferrer noopener">Health Insurers Surge After Medicare Agency Increases Payment Rates</a>
The benefit expense ratio was 86.4%, an increase of 80 basis points year over year, reflecting a higher Medicaid medical cost trend, partially offset by out-of-period premium taxes. Reuters noted that the analysts&#8217; average estimate was 86.8%.
&#8220;&#8230;In the first quarter, we made measurable progress reimagining the healthcare experience with personalized support, real-time digital solutions, and a whole-health model that improves outcomes and reduces cost&#8230;&#8221; said Gail Boudreaux, President and Chief Executive Officer
Last week, CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>),&nbsp;Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and Elevance Health stocks fell as investors were spooked after UnitedHealth Group, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) disappointing Q1 earnings and <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44860240/unitedhealth-slashes-2025-outlook-on-medicare-funding-reductions-stock-crashes" rel="noreferrer noopener">slashed 2025 guidance</a>.
The operating expense ratio was 10.9%, improving 70 basis points from the prior year. The adjusted operating expense ratio was 10.7%, an improvement of 60 basis points, primarily driven by expense leverage associated with growth in operating revenue and ongoing cost management, partially offset by out of period premium tax expense during the quarter.
Premiums rose 14.5% to $40.89 billion, product revenue rose 29.1% to $5.81 billion, and services fees fell marginally to $2.07 billion.
Adjusted earnings per share reached $11.97, up 10.8%, beating the consensus of $11.38.
The operating revenue of the health benefits segment was $41.4 billion in the first quarter of 2025, an 11% increase driven primarily by higher premium yields and growth in our Medicare Advantage and Individual ACA plan membership.
Medical membership totaled approximately 45.8 million as of March 31, 2025, an increase of 99 thousand from year-end 2024, driven by growth in Medicare Advantage and Commercial risk-based member, partially offset by a decline in Commercial fee-based membership from a known customer transition.
Operating revenue for Carelon was $16.7 billion, up 38%, driven by recent acquisitions in home health and pharmacy services, growth in CarelonRx product revenue, and the scaling of innovative risk-based capabilities in Carelon Services.
Guidance: Elevance Health reaffirms the 2025 adjusted EPS outlook of $34.15-$34.85 versus consensus of $34.22.
Price Action: ELV stock is up 1.87% at $414.31 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44907170/upcoming-pfizer-earnings-call-might-be-focused-on-tariffs-policy-risks-and-obesity-pipeline" target="_blank" rel="noreferrer noopener">Upcoming Pfizer Earnings Call Might Be Focused On Tariffs, Policy Risks And Obesity Pipeline</a></li>
</ul>
Photo via Shutterstock

Guidance

Health Care

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Despite Medicaid Pressure, Elevance Health Delivers Strong Q1 Performance, Reiterates Profit Outlook

HSBC analyst Sidharth Sahoo downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Buy to Hold.

Downgrades

HSBC Downgrades UnitedHealth Group to Hold

Morgan Stanley analyst Ricky Goldwasser maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $664 to $563.

Morgan Stanley Maintains Overweight on UnitedHealth Group, Lowers Price Target to $563

Though UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) reported disappointing first-quarter results last week, two analysts from KeyBanc Capital Markets and Truist Securities remain <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44902410/unitedhealth-group-stock-is-getting-crushed-whats-fueling-the-selloff">bullish on the stock. </a>
Expert Ideas: Both David MacDonald at Truist and Matthew Gillmor at KeyBanc said that although the health care giant's most recent quarter and 2025 earnings guidance missed the mark, they remain bullish on UnitedHealth for the long term. 
Read Next:<a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable"> UnitedHealth CEO Says High Cost Of US Health Care &#8216;Simply Not Sustainable&#8217;&nbsp;</a>
Both analysts said that while the Medicare Advantage utilization trend was troubling, its emergence early in the year will allow time for management to correct course.&nbsp; When coupled with the better-than-expected rate updates for 2026, the analysts see the company recovering into 2026.&nbsp;
The Truist analyst highlighted the narrowing Medicaid rate mismatch and upbeat selling season commentary from management.
KeyBanc sees a "silver lining" in UnitedHealth's ability to correct the RAF coding issues for 2026 and expects the company to factor the higher utilization rates into June bids. The analyst also said competitors like Humana and CVS are "not well positioned to take advantage of UNH's stumble."&nbsp;
The Takeaway: The analysts see UnitedHealth's issues as mostly isolated and "fixable" and maintained bullish ratings on the stock while slashing price targets.&nbsp;
KeyBanc maintained an Overweight rating on UnitedHealth shares, but lowered its price target from $650 to $575. Truist Securities maintained its Buy rating and lowered the price target for UnitedHealth stock from $660 to $580. 
UNH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro,</a> UnitedHealth shares ended Monday's session 6.35% lower at $425.33. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/04/44903087/amazon-stock-downgraded-price-target-slashed-as-tariffs-create-uncertainty">Amazon Stock Downgraded, Price Target Slashed As Tariffs Create Uncertainty&nbsp;</a></li>
</ul>

UnitedHealth Q1 Disappoints, But These Analysts Remain Bullish On The Stock

Argus Research analyst David Toung downgrades UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) from Buy to Hold.

Argus Research Downgrades UnitedHealth Group to Hold

Truist Securities analyst David Macdonald maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Buy and lowers the price target from $660 to $580.

Truist Securities Maintains Buy on UnitedHealth Group, Lowers Price Target to $580

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Monday on continued downside momentum from disappointing earnings last week. Multiple analysts also slashed price targets following the <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">company&#8217;s quarterly results</a>.
What Happened: UnitedHealth reported first-quarter revenue of $109.58 billion, missing analyst estimates of $111.6 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported first-quarter adjusted earnings of $7.20 per share, missing estimates of $7.29 per share.
UnitedHealth also cut its full-year 2025 outlook due to rising medical costs. The health insurer now expects full-year adjusted earnings of $26 to $26.50 per share, down from its prior outlook of $29.50 to $30 per share. Analysts had been expecting full-year earnings of $29.73 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates.
&#8220;UnitedHealth Group grew to serve more people more comprehensively but did not perform up to our expectations, and we are aggressively addressing those challenges to position us well for the years ahead, and return to our long-term earnings growth rate target of 13 to&nbsp;16%,&#8221; said Andrew Witty, CEO of UnitedHealth.
On the <a href="https://www.benzinga.com/general/health-care/25/04/44869920/unitedhealth-ceo-says-high-cost-of-us-health-care-simply-not-sustainable">conference call</a> following the print, Witty noted that health care in the U.S. is more expensive than it should be. He told investors and analysts that even common procedures can cost up to four times more in the U.S. than in other countries.
&#8220;It&#8217;s simply not sustainable,&#8221; Witty said.
Related Link: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44898701/stock-of-the-day-where-will-the-unitedhealth-selloff-end">Stock Of The Day – Where Will The UnitedHealth Selloff End?</a>
Analyst Changes:
<ul>
<li>Oppenheimer analyst Michael Wiederhorn maintained UnitedHealth with an Outperform and lowered the price target from&nbsp;$640&nbsp;to&nbsp;$600.</li>
</ul>
<ul>
<li>Raymond James analyst John Ransom reiterated UnitedHealth with a Strong Buy and cut the price target from&nbsp;$635&nbsp;to&nbsp;$540.</li>
</ul>
<ul>
<li>Keybanc analyst Tim Rezvan maintained UnitedHealth with an Overweight and cut the price target from&nbsp;$650&nbsp;to&nbsp;$575.</li>
</ul>
<ul>
<li>Barclays analyst Andrew Mok maintained UnitedHealth with an Overweight and cut the price target from&nbsp;$642&nbsp;to&nbsp;$560.</li>
</ul>
UNH Price Action: <a href="http://benzinga.com/quote/unh">UnitedHealth Group shares</a> closed the previous trading session down 22%. The stock was down another 5.09% at $431.00 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: <a href="https://www.shutterstock.com/g/JHVEPhoto">JHVEPhoto</a>/Shutterstock.

UnitedHealth Group Stock Is Getting Crushed: What's Fueling The Selloff?

A few thematic and leveraged ETFs shone last week, posting solid gains as other markets retreated due to worries over geopolitics and macroeconomic uncertainty. Across the spectrum, from biotech and streaming to crypto and transportation, some funds flashed decent returns.
T-Rex 2X Long DJT Daily Target ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/DJTU#BATS">DJTU</a>) jumped 33.5%, the week&#8217;s best performer as the Dow Jones Transportation Average recovered on Thursday.
Defiance Daily Target 2X Long LLY ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLYX#NYSE">LLYX</a>) rose 22.3% as Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares soared 11.34%. Investors remain optimistic about the company&#8217;s blockbuster weight-loss and diabetes medications, which continue to drive revenue growth and provide robust forward guidance.
Direxion Daily NFLX Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFXL#NASDAQ">NFXL</a>) gained 8.8%, echoing the<a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering"> robust quarterly performance</a> of Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>). The streaming behemoth surpassed Wall Street expectations, with the increase in its ad-supported plan and better content performance providing bulls a reason to rejoice.
SPDR Galaxy Digital Asset Ecosystem ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DECO#NASDAQ">DECO</a>) gained 5.5% as stabilizing Bitcoin prices and increasing institutional interest in digital asset infrastructure supported it. Favorable sentiment in the overall crypto market helped support the fund&#8217;s holdings in blockchain and crypto-exposed assets.
Yieldmax MSTR Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSTY#NYSE">MSTY</a>) increased by 3%, taking advantage of MicroStrategy&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) solid performance and consistent returns earned from its options-based income strategy based on Bitcoin.
These ETF profits were impressive compared to the broader market&#8217;s losses during the last holiday-shortened week.
What Happened In The Markets Last Week
Markets were rattled by fresh geopolitical tensions and hawkish central bank commentary. The largest drag was from the technology sector, following Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) announcement that it had been informed by the Trump administration that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44886016/nvidias-do-not-enter-sign-caught-in-a-category-5-tariff-storm">exports of its H20 AI chip to China </a>would need a license. The firm warned that the export controls would lower earnings by $5.5 billion, pushing its shares down 8.5%. The news also <a href="https://www.benzinga.com/25/04/44799456/chip-shock-3-hot-semiconductor-etfs-to-watch-as-trumps-tariff-bomb-ticks">affected the wider chip industry</a>, with the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) losing 3%—its seventh loss in the last eight weeks.
Earnings were mixed. While banks and Netflix reported positive results, UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) surprised markets by cutting its full-year forecast. The stock lost 22.4% in one session—the worst one-day decline for the insurer since 1998.
On the trade side, Canada temporarily paused counter measure tariffs on critical U.S. imports to relieve cross-border supply chain stress—most notably helping Midwest-based auto manufacturers.
Meanwhile, Federal Reserve Chairman Jerome Powell again expressed reluctance to cut interest rates, citing lingering inflation and risks to trade-driven growth. President Donald Trump condemned the move, calling Powell &#8220;always too late&#8221; and threatening to fire him before his term ends in May 2026. Trump spoke against a backdrop of irritation over the European Central Bank&#8217;s sixth consecutive interest rate reduction, further amplifying the divergence of monetary policies in developed nations.
Against this background of policy uncertainty and volatility, gold was the shining star. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) jumped to an all-time high of $3,330 per ounce, recording gains in 14 of the last 16 weeks, as investors flocked to the yellow metal for safety.
While headwinds beset the overall market, last week&#8217;s ETF action highlights where momentum—and investor confidence—is still present.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44876466/the-10k-handbag-hoax-tiktoks-trade-war-puts-luxury-etfs-in-the-hot-seat">The $10K Handbag Hoax? TikTok&#8217;s Trade War Puts Luxury ETFs In The Hot Seat</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

DECO

DJTU

LLYX

MSTR

Tidal Trust II YieldMax MSTR Option Income Strategy ETF

MSTY

NFLX

NFXL

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

ETFs Last Week: Thematic ETFs Gleamed Against Market Gloom

Barclays analyst Andrew Mok maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $642 to $560.

Barclays Maintains Overweight on UnitedHealth Group, Lowers Price Target to $560

Press Releases

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of UnitedHealth Group Incorporated - UNH

Legal

UNH Announcement: UnitedHealth Group Investors Are Encouraged to Contact The Rosen Law Firm About Ongoing Investigation of Breaches of Fiduciary Duties by the Directors and Officers – UNH

UnitedHealth Group Reports First Quarter 2025 Results and Revises Full Year Guidance

Rosen Law Firm Encourages UnitedHealth Group Incorporated Investors to Inquire About Securities Class Action Investigation – UNH

UNH Investor News: Rosen Law Firm Encourages UnitedHealth Group Incorporated Investors to Inquire About Securities Class Action Investigation - UNH

UNH Announcement: If You Have Suffered Losses in UnitedHealth Group Incorporated (NYSE: UNH), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Ademi & Fruchter LLP Investigates Claims of Securities Fraud against UnitedHealth Group Incorporated

Rosen Law Firm Encourages UnitedHealth Group Incorporated Investors to Inquire About Securities Class Action Investigation - UNH

UNH Announcement: If You Have Suffered Losses in UnitedHealth Group Incorporated (NYSE: UNH) You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

UnitedHealth Group

UnitedHealth Group (UNH) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル